| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6521260 | NOVARTIS | Carrier particles for use in dry powder inhalers |
Jan, 2016
(8 years ago) | |
| US6582678 | NOVARTIS | Carrier particles for use in dry powder inhalers |
Apr, 2018
(6 years ago) | |
| US8658673 | NOVARTIS | BETA2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US8796307 | NOVARTIS | Beta2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US7820694 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US8067437 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US8283362 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US8029768 | NOVARTIS | Treatment of respiratory diseases |
Apr, 2021
(3 years ago) | |
| US7229607 | NOVARTIS | Treatment of respiratory disease |
Apr, 2021
(3 years ago) | |
| US9962338 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8303991 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8048451 | NOVARTIS | Pharmaceutical compositions for inhalation |
Jun, 2021
(2 years ago) | |
| US9931304 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US7736670 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8580306 | NOVARTIS | Particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8956661 | NOVARTIS | Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof |
Jun, 2021
(2 years ago) | |
| US8435567 | NOVARTIS | Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation |
Jun, 2021
(2 years ago) | |
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(4 years from now) | |
| US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(4 years from now) | |
Utibron is owned by Novartis.
Utibron contains Glycopyrrolate; Indacaterol Maleate.
Utibron has a total of 20 drug patents out of which 17 drug patents have expired.
Expired drug patents of Utibron are:
- US6521260
- US6582678
- US8658673
- US8796307
- US7820694
- US8067437
- US8283362
- US8029768
- US7229607
- US9962338
- US8303991
- US8048451
- US9931304
- US7736670
- US8580306
- US8956661
- US8435567
Utibron was authorised for market use on 29 October, 2015.
Utibron is available in powder;inhalation dosage forms.
Utibron can be used as long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).
Drug patent challenges can be filed against Utibron from 02 July, 2015.
The generics of Utibron are possible to be released after 20 October, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Product(NP) | Oct 29, 2018 |
Drugs and Companies using GLYCOPYRROLATE; INDACATEROL MALEATE ingredient
NCE-1 date: 02 July, 2015
Market Authorisation Date: 29 October, 2015
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER;INHALATION
UTIBRON family patents
